The Fast Lane of Hypoxic Adaptation: Glucose Transport Is Modulated via A HIF-Hydroxylase-AMPK-Axis in Jejunum Epithelium

Franziska Dengler * and Gotthold Gäbel

Institute of Veterinary Physiology, University of Leipzig, 04103 Leipzig, Germany; gaebel@rz.uni-leipzig.de

* Correspondence: dengler@vmf.uni-leipzig.de; Tel.: +49-341-97-38-073

Received: 20 August 2019; Accepted: 8 October 2019; Published: 9 October 2019

Abstract: The intestinal epithelium is able to adapt to varying blood flow and, thus, oxygen availability. Still, the adaptation fails under pathologic situations. A better understanding of the mechanisms underlying the epithelial adaptation to hypoxia could help to improve the therapeutic approach. We hypothesized that the short-term adaptation to hypoxia is mediated via AMP-activated protein kinase (AMPK) and that it is coupled to the long-term adaptation by a common regulation mechanism, the HIF-hydroxylase enzymes. Further, we hypothesized the transepithelial transport of glucose to be part of this short-term adaptation. We conducted Ussing chamber studies using isolated lagomorph jejunum epithelium and cell culture experiments with CaCo-2 cells. The epithelia and cells were incubated under 100% and 21% O\textsubscript{2}, respectively, with the panhydroxylase inhibitor dimethyloxalylglycine (DMOG) or under 1% O\textsubscript{2}. We showed an activation of AMPK under hypoxia and after incubation with DMOG by Western blot. This could be related to functional effects like an impairment of Na\textsuperscript{+}-coupled glucose transport. Inhibitor studies revealed a recruitment of glucose transporter 1 under hypoxia, but not after incubation with DMOG. Summing up, we showed an influence of hydroxylase enzymes on AMPK activity and similarities between hypoxia and the effects of hydroxylase inhibition on functional changes.

Keywords: jejunum epithelium; hypoxia; AMPK; HIF hydroxylase; glucose transport; SGLT1; GLUT1; GLUT2

1. Introduction

Hypoxia is defined as “a state of cellular oxygen deprivation whereby the O\textsubscript{2} requirements of a cell exceed that of available O\textsubscript{2}” [1]. The gastrointestinal tract is familiar with large oxygen gradients due to its localization at the border between the anaerobic lumen and the mesenterial vessels, as well as its varying perfusion through the latter. It has been established that the intestinal epithelium is able to adapt to these circumstances elaborately, existing in a state of ‘physiological hypoxia’ [1]. However, under pathologic conditions accompanied by hypoxia, such as strangulation of the small intestines, hypoperfusion, or inflammatory disease [2,3], this adaptation seems to fail. A better understanding of the adaptation reaction involved in epithelial survival could help to improve the therapeutic approach to hypoxia in a pathologic context.

The underlying adaptation mechanisms remain elusive. While hypoxia-inducible factor (HIF) is considered to be the ‘master regulator’ of adaptation to hypoxia [4], its main mode of action is on the transcriptional level and, thus, it takes some time for the adaptation reaction to be effective. However, for the epithelium’s survival under challenging circumstances such as a sudden onset of hypoxia, an adaptation within minutes is necessary. Recent research provided evidence for a fast adaptation to hypoxia taking place on the protein rather than on the gene expression level [5,6]. This quick reaction
might at least bridge the critical time until HIF-mediated adaptation mechanisms are set to work and could, thus, be a critical point for early therapeutic intervention.

A crucial aspect of this adaptation seems to be the supply of the enterocytes with energy sources, i.e., mainly glucose and amino acids. Kles and Tappenden [7] reported that the transepithelial transport of glucose was impaired under hypoxia, while glutamine transport was not. In accordance with that, it has been shown that the activity of the sodium-coupled glucose transporter SGLT1 was diminished under hypoxia in jejunum epithelium [5,8,9]. This downregulation appears to be a targeted and reasoned adaptation rather than a sign of cellular failure. Accordingly, the total transepithelial transport of glucose is sustained in spite of the missing import via SGLT1 [5]. Some authors postulate a recruitment of glucose transporter 2 (GLUT2) to the apical membrane in order to enhance the energy-independent uptake of glucose [9–11]. This switch from energy-dependent uptake to facilitated diffusion infers the advantage that the glucose supply could be sustained while less ATP is consumed by the enterocytes for its uptake. Thus, the available ATP originating rather from anaerobic glycolysis under hypoxia, which is way less effective compared to aerobic glycolysis, is used economically.

While the exact transport systems involved in this adaptation are still under discussion and need further investigation, it is also not clear yet by which intracellular mechanism this fast adaptation is mediated. Our own previous work indicated an involvement of the AMP-activated protein kinase (AMPK) in the modulation of transepithelial glucose transport in the lagomorph jejunum epithelium [5]. An activation of AMPK under hypoxia has also been postulated in human airway epithelial cells, HeLa cells, as well as prostate carcinoma cells [12–14]. AMPK is an ubiquitously expressed serine/threonine kinase monitoring cellular energy levels [15,16]. It is activated by phosphorylation on Thr172 of the α subunit [16]. Binding of AMP to the γ subunit promotes this phosphorylation of the α subunit that can be mediated by at least two different upstream kinases: liver kinase B (LKB) 1 and Ca²⁺/calmodulin-dependent protein kinase kinase (CAMKK) 2 [17,18]. Additionally, the allosteric binding of AMP prevents it from dephosphorylation, thus coupling its activity tightly to cellular energy levels [19]. In general, AMPK deactivates anabolic, energy-consuming processes and activates catabolic, energy-delivering processes, e.g., by phosphorylation of acetyl-CoA carboxylase (ACC), the rate limiting enzyme for fatty acid synthesis, and of phosphofructokinase, enhancing glycolysis, respectively, thus ameliorating the cellular ATP supply [17,20].

However, our own and others’ results strongly indicate that hypoxia does not lead to an immediate and complete depletion of ATP, although aerobic glycolysis might be disabled under hypoxia [5,21]. Thus, the activation of AMPK under hypoxia is not necessarily initiated by an increased AMP/ATP ratio, but alternate mechanisms activating AMPK under hypoxia have to be taken into account in the intestinal epithelial cells. Thus, there might be energy-independent ways of activating AMPK that have not been elucidated yet, anticipating the critical situation before the cells are damaged severely.

One of them could be the HIF-prolyl-4-hydroxylases (PHDs). PHDs are the central sensors of cellular oxygen supply and control the adaptation to hypoxia by mediating an oxygen-dependent hydroxylation of the cytoplasmic α subunit of HIF [22]. This oxygen-induced hydroxylation leads to the degradation of HIFα. Under hypoxia, the hydroxylation reaction ceases due to the lack of the cofactor oxygen and, thus, HIFα is stabilized and able to translocate into the nucleus where it dimerizes with the β subunit and modulates the transcription of >300 genes involved in metabolism, angiogenesis, and proliferation, in order to adjust the cellular functions to the hypoxic conditions [23,24]. Additionally, a second oxygen-dependent repression of HIF transcriptional activity is regulated by asparaginyl hydroxylation: another hydroxylase (factor inhibiting HIF, FIH) hydroxylates an asparagine residue within HIFα subunits, resulting in steric inhibition of its interaction with the transcriptional co-activator p300/CBP, thereby inhibiting HIF-dependent transcription [25,26].

Besides regulating HIF, there are already studies hinting at an activation of AMPK by FIH inhibition in brown adipose tissue [27]. A coupling of the long-term (HIF-mediated) and the short-term (AMPK-mediated) adaptation by a common pathway would be the ideal way of coordinating the adaptation reactions. As outlined above, HIF-hydroxylases might be that common pathway. Thus,
we hypothesize AMPK under the control of PHDs/FIH to be the “fast lane” in hypoxic adaptation of the intestinal epithelium.

Therefore, we wanted to investigate if hydroxylase enzymes play a role in the activation of AMPK under hypoxia in jejunal epithelium and how functional effects regarding the alteration of glucose transport are implemented. Therefore, we employed a combined approach using the advantages of the functional Ussing chamber technique and a cell line enabling a more detailed molecular examination. In this study, we show proof of an activation of AMPK by the panhydroxylase inhibitor dimethyloxalylglycine (DMOG) and similar effects of hydroxylase inhibition and hypoxia on glucose transport across jejunal epithelium.

2. Results

2.1. The Panhydroxylase Inhibitor DMOG Mimics the Effect of Hypoxia on SGLT1 Activity

Previously, we showed a reduced activity of SGLT1 under hypoxia in lagomorph jejunal epithelium and an involvement of AMPK in its downregulation [5]. In order to test our hypothesis that AMPK is under the control of the PHDs and thus responsive to hypoxia, we preincubated the epithelia with the panhydroxylase inhibitor DMOG before submitting part of the epithelia to hypoxia. Subsequently, we added its inhibitor, phlorizin [28], to the mucosal buffer solution to determine the activity of SGLT1. Addition of phlorizin led to a drop in transepithelial short-circuit current (Isc). To correct the decrease in Isc induced by phlorizin, i.e., the SGLT1-dependent current, for the time-dependent decrease, we determined the activity of SGLT1. After equilibration in the buffer solution to determine the activity of SGLT1, half of the epithelia were preincubated with 2 mM DMOG for 15 min. Subsequently, part of the control and part of the DMOG group was subjected to ‘hypoxia’. After 45 min of ‘hypoxia’, 0.2 mM phlorizin was added to the mucosal buffer solution and the slopes of Isc for one minute before (mb) and after (ma) the addition were calculated as outlined in the Materials and Methods section and exemplified on the left hand (a). The difference in the slopes (Δm = mbl - mab) after mucosal addition of phlorizin (i.e., the effect of SGLT1 inhibition) was calculated and compared between the treatment groups. (b) shows that Δm was decreased by ‘hypoxia’ (grey bars) compared to the control group gassed with 100% oxygen (white bars) and also by preincubation with DMOG (hatched bars). Bars represent mean ± SD; one-way repeated measurements ANOVA with a subsequent Holm–Sidak test based on N = 6 (animals) (n = 10 (epithelia)), p < 0.05, different letters indicate significant differences between groups.

We found a significant decrease of Δm under hypoxia compared to control conditions (p < 0.05) and after preincubation with DMOG compared to the respective group of similarly gassed epithelia incubated without DMOG (p < 0.05). However, there was no difference between epithelia incubated...
under hypoxia only and with DMOG only (under 100% O₂ gassing). This indicates that inhibition of the PHDs mimics the effect of hypoxia on the activity of SGLT1. The larger decrease of Δm by DMOG incubation under hypoxia (39 ± 25 µEq cm⁻² h⁻¹ min⁻¹) compared to hypoxia alone (190 ± 172 µEq cm⁻² h⁻¹ min⁻¹) hints at a stronger or additive effect of DMOG compared to hypoxia.

2.2. Transepithelial Glucose Transport Is Sensitive to STF-31 under Hypoxia Only

With the activity of SGLT1 being decreased under hypoxia, we were wondering if other transporters may sustain the transepithelial transport of glucose, as we could show before [5]. To investigate this, we measured transepithelial fluxes of ¹⁴C-glucose and incubated the epithelia with inhibitors for either SGLT1 (phlorizin), GLUT1 (STF-31), or GLUT2 (cytochalasin B) on the mucosal side. Comparison of the groups revealed (i) no difference between Jmsglucose under hypoxia and control conditions, i.e., 100% O₂, and (ii) a sensitivity of transepithelial glucose transport to phlorizin and cytochalasin B under both control and hypoxic conditions (Figure 2). Under hypoxia, however, we also observed a decreased flux rate after preincubation with the GLUT1 inhibitor STF-31, which was not observed under control conditions (Figure 2). This indicates a more important role for GLUT1 in transepithelial glucose transport under hypoxia.

![Figure 2](image-url)

**Figure 2.** Jmsglucose across isolated lagomorph jejunum epithelia after the incubation with inhibitors for SGLT1 and glucose transporters GLUT2 and GLUT1. Jmsglucose was similar under hypoxia and gassing with 100% O₂. While Jmsglucose was decreased significantly by phlorizin (inhibiting SGLT1, light grey bars) and cytochalasin B (inhibiting GLUT2, dark grey bars) under both gassing regimes, STF-31 (inhibiting GLUT1, white bars) had an effect under hypoxia (hatched bars) only. Bars represent mean ± SD; one-way repeated measurements ANOVA with a subsequent Holm–Sidak test based on N = 6 (n = 12), p < 0.05, different letters indicate significantly different flux rates within each group.

Based on this observation, we intended to test whether preincubating the epithelia with DMOG would mimic the effects of hypoxia in this regard as well. However, there was no effect of STF-31 in these experiments (Figure 3). It must be taken into consideration though, that Jmsglucose was lower in the epithelia incubated with DMOG (Figure 3) compared to the experiments without DMOG preincubation before (Figure 2), i.e., on the same level Jmsglucose reached after addition of the inhibitors in the previous experimental series. Thus, there might be other effects of DMOG on transepithelial glucose transport besides a possible activation of AMPK, maybe masking the effect of STF-31.
Panhydroxylase Inhibition Results in an Activation of AMPK

To investigate the effects of panhydroxylase inhibition further on the cellular level, we used a CaCo-2 cell line, which is known to resemble the small intestinal epithelium [29]. The cells were incubated with or without 3 mM DMOG (under 21% O₂) or in 1% O₂ for 0.5, 1, 3, 6, and 24 h. Then, the activation of AMPK was assessed by measuring the phosphorylation grade of AMPK α as well as its target ACC. The ratio of pACC/ACC measured by Western blot was increased significantly after 0.5 h of incubation with DMOG, but not after 1 h of hypoxia (p < 0.01, one-way repeated measurements ANOVA). Longer incubation times did not increase the pACC/ACC ratio compared to the control group incubated at 21% O₂. A similar time course was observed for the pAMPKα/AMPKα ratio. After 0.5 and 1 h of DMOG treatment, the pAMPKα/AMPKα ratio was significantly increased compared to the control group incubated at 21% O₂ but also compared to the hypoxic group (Figure 4b, p < 0.05, one-way repeated measurements ANOVA). We can only speculate why the activation indicated by the increased pACC/ACC ratio after hypoxic incubation is not mirrored in the pAMPKα/AMPKα ratio as well. Assuming that the phosphorylation of AMPK precedes the phosphorylation of its targets, the phosphorylation of AMPKα may have been only transient and already gone after 0.5 h of incubation under hypoxia, but with DMOG being a more potent activator it may still have been visible under this treatment.

**Figure 3.** J_{msglucose} across isolated lagomorph jejunum epithelia after preincubation with DMOG and with or without the GLUT1-inhibitor STF-31. Epithelia were incubated as described above but preincubated with 2 mM DMOG instead of simulating hypoxia. J_{msglucose} was not significantly different between epithelia preincubated with DMOG only and epithelia incubated with DMOG and STF-31 (inhibiting GLUT1). There is no significant difference between the groups. Bars represent mean ± SD; N = 6 (n = 12) for DMOG only and N = 4 (n = 8) for DMOG + STF-31.

2.3. Panhydroxylase Inhibition Results in an Activation of AMPK

...
Figure 4. Activation of AMP-activated protein kinase (AMPK) in CaCo-2 cells as indicated by the phosphorylation of AMPKα and its target ACC. Cells were incubated under 21% O₂ (white bars), with 3 mM DMOG (hatched bars) or kept at 1% O₂ (grey bars) for 0.5, 1, 3, 6, or 24 h, as indicated at the x-axis. Total protein was extracted, separated by SDS-PAGE and AMPKα, ACC, pAMPKα, and pACC were detected using Western blot. (a) The ratio of pACC/ACC was increased after 0.5 h in both treatment groups and after 1 h of incubation with DMOG. Longer incubation times did not increase pACC compared to the control group incubated at 21% O₂. (b) The ratio pAMPKα/AMPKα was increased after incubation with DMOG for 0.5 and 1 h as well. However, there was no significant increase after hypoxic incubation compared to the control group incubated at 21% O₂. Longer incubation times had no effect. Boxes show the median, 10th, 25th, 75th, and 90th percentile plus error bars. Outliers are represented by dots. One-way repeated measurements ANOVA, p < 0.01, N = 4 (n = 8) for 6 h, N = 3 (n = 6) for 24 and 3 h, N = 5 (n = 10) for 1 and 0.5 h. Right side: representative blots after 0.5 and 1 h incubation time.

2.4. Total Protein Expression of SGLT1, GLUT1, and GLUT2 Is Not Affected by DMOG or Hypoxia but Phosphorylation of GLUT1 Is Increased by Hypoxia Only

Looking for an explanation for the previously observed decreased SGLT1 activity under hypoxia, we also assessed the protein expression of this transporter in CaCo-2 cells, along with that of GLUT1 and 2 by Western blot. In the total protein extracted from the cells (treatment of 0.5 and 1 h, see above), we did not detect any differences in the protein expression of these transporters (Figure 5).
we could identify a significant increase after 0.5 h of hypoxia compared to cells incubated at 21% O\textsubscript{2} (Figure 6, paired t-test, incubation with DMOG, respectively (Figure 7). We observed no significant changes in the gene expression after 1 h hypoxia and incubation with DMOG. There is no significant difference between the treatments. Representative blots are shown below. Boxes show the median, 10th, 25th, 75th, and 90th percentile plus error bars. Outliers are represented by dots. Paired t-test, $N = 5$ ($n = 10$) for 0.5 h and $N = 6$ ($n = 12$) for 1 h.

However, when using an antibody specific for GLUT1 phosphorylated at Ser226 (pGLUT1), we could identify a significant increase after 0.5 h of hypoxia compared to cells incubated at 21% O\textsubscript{2} (Figure 6, paired t-test, $p < 0.05$). DMOG, in contrast, had no effect.

2.5. mRNA Expression of SGLT1, GLUT1, and GLUT2 Is Not Affected by DMOG or Hypoxia

Besides protein expression, we also assessed the mRNA expression of SGLT1, GLUT1 and 2 in CaCo-2 cells incubated under 21% O\textsubscript{2} with or without DMOG or under hypoxia, as well as in isolated lagomorph jejunum epithelium after incubation in Ussing chambers under 100% O\textsubscript{2} or 1% O\textsubscript{2} with or without DMOG. We observed no significant changes in the gene expression after 1 h hypoxia and incubation with DMOG, respectively (Figure 7).
we postulated the import of glucose to be one of these crucial functions and, thus, a modulation of the AMPK, which has been shown to downregulate SGLT1 under hypoxia before [5], is under the control of GLUT2 being localized at the basolateral membrane only, this was quite surprising and cannot be explained sufficiently here. One might well doubt the specificity of these inhibitors, especially with cytochalasin B acting as a disruptor of the cytoskeleton [31,32]. Casting this aside, however, the most important finding of this experiment was an effect of STF-31, a GLUT1-inhibitor [33,34], under hypoxia only. This indicates that SGLT1 is indeed supplemented by another transport mechanism, i.e., GLUT1, although not by GLUT2 as postulated before [10,30,35]. This fits very well with GLUT1 gene transcription also being a HIF target [23], thus the long-term adaptation would support the modulations initiated in the short run. As outlined above, the replacement of glucose transport via SGLT1 by GLUT1 would be energetically less expensive for the cells. Additionally, it may be assumed that under hypoxia, the transepithelial transport of glucose has been reported to be stable under hypoxia [5,30], which was confirmed by the experiments presented herein (Figure 2).

Looking for the transport mechanism responsible for sustaining the transepithelial transport of glucose by AMPK under hypoxia. We reproduced previous results that showed a reduced activity of SGLT1 in small intestinal epithelium under hypoxia [5,7]. Additionally, we showed that preincubation with DMOG has a similar effect on the SGLT1-dependent I\textsubscript{sc} (Figure 1), supporting our mechanistic hypothesis that AMPK, which has been shown to downregulate SGLT1 under hypoxia before [5], is under the control of hydroxylases.

Still, it is not clear yet, how the transepithelial transport of glucose is mediated under hypoxia. In spite of a reduced SGLT1 activity, the transepithelial transport of glucose has been reported to be stable under hypoxia [5,30], which was confirmed by the experiments presented herein (Figure 2). Looking for the transport mechanism responsible for sustaining the transepithelial transport of glucose, we used several inhibitors for flux measurements of 14C-glucose (Figure 2). We found inhibitory effects of the SGLT1-inhibitor phlorizin and the GLUT2-inhibitor cytochalasin B to be similar both under 1% and 100% O2. With respect to the aforementioned reduced activity of SGLT1 under hypoxia and the established view of GLUT2 being localized at the basolateral membrane only, this was quite surprising and cannot be explained sufficiently here. One might well doubt the specificity of these inhibitors, especially with cytochalasin B acting as a disruptor of the cytoskeleton [31,32]. Casting this aside, however, the most important finding of this experiment was an effect of STF-31, a GLUT1-inhibitor [33,34], under hypoxia only. This indicates that SGLT1 is indeed supplemented by another transport mechanism, i.e., GLUT1, although not by GLUT2 as postulated before [10,30,35]. This fits very well with GLUT1 gene transcription also being a HIF target [23], thus the long-term adaptation would support the modulations initiated in the short run. As outlined above, the replacement of glucose transport via SGLT1 by GLUT1 would be energetically less expensive for the cells. Additionally, it may be assumed that under hypoxia, the transepithelial transport of glucose has been reported to be stable under hypoxia [5,30], which was confirmed by the experiments presented herein (Figure 2).

Looking for the transport mechanism responsible for sustaining the transepithelial transport of glucose by AMPK under hypoxia. We reproduced previous results that showed a reduced activity of SGLT1 in small intestinal epithelium under hypoxia [5,7]. Additionally, we showed that preincubation with DMOG has a similar effect on the SGLT1-dependent I\textsubscript{sc} (Figure 1), supporting our mechanistic hypothesis that AMPK, which has been shown to downregulate SGLT1 under hypoxia before [5], is under the control of hydroxylases.

Still, it is not clear yet, how the transepithelial transport of glucose is mediated under hypoxia. In spite of a reduced SGLT1 activity, the transepithelial transport of glucose has been reported to be stable under hypoxia [5,30], which was confirmed by the experiments presented herein (Figure 2). Looking for the transport mechanism responsible for sustaining the transepithelial transport of glucose, we used several inhibitors for flux measurements of 14C-glucose (Figure 2). We found inhibitory effects of the SGLT1-inhibitor phlorizin and the GLUT2-inhibitor cytochalasin B to be similar both under 1% and 100% O2. With respect to the aforementioned reduced activity of SGLT1 under hypoxia and the established view of GLUT2 being localized at the basolateral membrane only, this was quite surprising and cannot be explained sufficiently here. One might well doubt the specificity of these inhibitors, especially with cytochalasin B acting as a disruptor of the cytoskeleton [31,32]. Casting this aside, however, the most important finding of this experiment was an effect of STF-31, a GLUT1-inhibitor [33,34], under hypoxia only. This indicates that SGLT1 is indeed supplemented by another transport mechanism, i.e., GLUT1, although not by GLUT2 as postulated before [10,30,35]. This fits very well with GLUT1 gene transcription also being a HIF target [23], thus the long-term adaptation would support the modulations initiated in the short run. As outlined above, the replacement of glucose transport via SGLT1 by GLUT1 would be energetically less expensive for the cells. Additionally, it may be assumed that under hypoxia, the transepithelial transport of glucose has been reported to be stable under hypoxia [5,30], which was confirmed by the experiments presented herein (Figure 2).
hypoxia the enterocytes consume more glucose themselves in order to generate ATP by anaerobic
glycolysis and, thus, the concentration gradient necessary for the import of glucose via GLUT1 is kept
up. Although we found the transepithelial transport of $^{14}$C-glucose to be stable under hypoxia and
control conditions, it has to be kept in mind that the measurement of $^{14}$C cannot discriminate between
the original substrate glucose and its metabolites that may be extruded to the serosal side.

To explain the modifications observed in transepithelial glucose transport, we assessed the gene
and protein expression of SGLT1, GLUT1 and 2. However, we did not observe changes, neither on
the protein (Figure 5) nor the gene expression level (Figure 7) of any of the transporters. The lack
of differences in the mRNA expression after 1 h of incubation is not surprising, as HIF-dependent
gene transcription regulation becomes effective one hour after the onset of hypoxia at the earliest.
Nonetheless this finding is in accordance with others’ observations showing no changes in total protein
expression of SGLT1 after hypoxia [7] or under activation of the AMPK pathway [36]. However,
differences in SGLT1 brush border membrane localization in rat jejunum epithelium after simulation of
hypoxia in vivo [7], as well as an increased amount of GLUT2 in the brush border membrane after
incubation with an AMPK agonist [36] have been described. This is in accordance with our assumption
that AMPK mediates these functional changes, which is known to be effective via phosphorylation
of its targets. Therefore, the total protein concentration might remain unchanged while the amount
of phosphorylated, and thus membrane-bound, transporter is modulated. A modulation of existing
transporter proteins is reflected by our findings of an increased phosphorylation of GLUT1 after 0.5 h of
hypoxia (Figure 6). Lee et al. (2015) previously described a phosphorylation-dependent enhancement
of GLUT1-mediated glucose transport in erythrocytes and endothelial cells [37]. The observation that
pGLUT1 is increased only after hypoxic incubation but not by DMOG is in accordance with our results
from the functional studies, which also indicated a recruitment of GLUT1 only after hypoxia but not
after DMOG pretreatment. Thus, AMPK is either activated by other means than PHDs under hypoxia
or another, hydroxylase-independent, pathway is responsible for the recruitment of GLUT1 under
hypoxia. A phosphorylation of SGLT1 should be investigated further in future studies, although it
might be limited by the availability of commercial antibodies.

Apart from the recruitment of GLUT1, we also found indicators for an activation of AMPK under
hypoxia controlled by PHDs/FIH. We used the panhydroxylase inhibitor, DMOG, in functional studies,
as well as studies on the molecular level. Several results favor our hypothesis: We could achieve
an activation of AMPK by incubation with DMOG in CaCo-2 cells (Figure 4), indicating that AMPK
activity is actually controlled by hydroxylation under normoxia and could thus be regulated along
with HIF. Similar results have been obtained before in neonatal rat cardiomyocytes incubated with
DMOG, in which besides an activation of AMPK, a stabilization of HIF could also be shown [38].
In contrast to our study, however, Yan et al. (2012) found the activation of AMPK and HIF not only
for a short period of incubation with DMOG but for up to 9 h [38]. We could detect only a transient
activation of AMPK under hypoxia/DMOG incubation lasting for 1 h. Other studies also found a
maximum of AMPK activity after 60 min of hypoxia followed by a subsequent decline [13,39], showing
a coherence of the vanishing AMPK activation with a gradually increasing HIF stabilization [13].
All these observations support our hypothesis of AMPK being the quick way for adaptation until HIF
takes over. However, it has to be kept in mind that DMOG is a rather unspecific inhibitor and further
studies on the PHD-AMPK axis with more specific inhibitors or knock outs for the PHDs are needed to
prove this.

While Tan et al. [14] could only confirm the “classical” way for AMPK activation, i.e., an increased
AMP:ATP ratio, under hypoxia, others postulate additional modes. CAMKK is considered
to be activated via reactive oxygen species generated under hypoxia [13,40,41] or—supporting
our hypothesis—via hydroxylation by the PHDs in cardiomyocytes and epithelial cell lines [38].
An involvement of CAMKK is further strengthened by the finding that silencing PHD2 in
cardiomyocytes induced an activation of AMPK similar to the effect of DMOG, but had no effect when a
Ca$^{2+}$-chelator was added [38]. In brown adipose tissue, in contrast, FIH was shown to regulate AMPK
by direct hydroxylation [27]. While not much is known regarding the proline-hydroxylation of non-HIF targets so far, asparagine hydroxylation by FIH is more common and has been demonstrated for multiple non-HIF proteins, including pathways involving AMPK [26], and might thus be more likely.

Supporting our view, we found similar effects of DMOG and hypoxia on the gene and protein expression of the glucose transporters (Figures 5 and 7) and on the activity of SGLT1 measured in isolated lagomorph jejunum epithelia in Ussing chambers (Figure 1).

When investigating the functional effects of DMOG on SGLT1 activity, however, we found a more pronounced effect of DMOG than that of hypoxia alone (Figure 1). This could be due to a higher impact of the inhibitor compared to the 1% oxygen gassing, but also an additive effect of both might be taken into consideration. A higher impact of DMOG is also supported by the observation that the activation of AMPK is slightly more pronounced and lasts longer than under hypoxia in the CaCo-2 cells (Figure 4). Yan et al. (2012) reported a smaller effect of knocking out PHD2 compared to an application of the panhydroxylase inhibitor on AMPK activity [38]. This indicates that there might be more than one hydroxylase enzyme working redundantly. However, we used a rather unspecific panhydroxylase inhibitor and further studies employing more specific inhibitors, distinct knock outs, or siRNA approaches are necessary to identify specific enzymes involved in the regulation of AMPK, as well as its crosstalk with HIF.

Summing up, we could show an influence of hydroxylase enzymes on AMPK activity and similarities between hypoxia and the effects of hydroxylase inhibition. However, the effects differ in some aspects, again documenting that hypoxic signaling is no simple story but a complex interplay of numerous factors that might even be interchangeable. The inhibition of PHDs is considered an interesting target for the treatment of several pathological conditions, like anemia originating from chronic kidney disease or inflammatory bowel disease [22]. Thus, a profound knowledge of other pathways controlled by PHDs that might also be targeted by clinical drugs aimed at the regulation of HIF, is necessary to understand their potential side effects, both positive and negative.

4. Materials and Methods

4.1. Ussing Chamber Experiments

4.1.1. Animals and Tissue Sampling

The Ussing chamber experiments were conducted as described before [5]. Briefly, 6- to 24-month-old rabbits (Vienna Blue and White or New Zealand Red Rabbit) of both sexes were fed a standard diet consisting of water and hay ad libitum, carrots, and a standard rabbit concentrate formula for at least ten days before slaughter. The animals were killed by exsanguination after captive bolt stunning. Then, the abdominal cavity was opened, and the mid-jejunum was excised, opened along the mesenteric border, and rinsed and submerged in 37 °C warm oxygenated buffer solution. After transport to the laboratory, the epithelium was stripped off the muscle layers manually and mounted in Ussing chambers as described previously [5]. The area exposed accounted for 1.1 cm². The epithelia were allowed to equilibrate in the system for at least 30 min before conducting the experiment.

The experiments were conducted in accordance with the EU directive 2010/63/EU and the German legislation on the protection of animals. They were reported to the Landesdirektion Leipzig as T 46/14 (date of approval 21 October 2014).

4.1.2. Buffer Solutions and Gassing

The buffer solutions were prepared with chemicals obtained from Sigma-Aldrich (Darmstadt, Germany), Carl Roth (Karlsruhe, Germany), VWR (Darmstadt, Germany), or Merck (Darmstadt, Germany), unless stated otherwise. The gasses were procured from Air Liquide (Düsseldorf, Germany).

In all of the experiments, a basal buffer solution consisting of 120 mM NaCl, 5.5 mM KCl, 1.25 mM CaCl₂, 1.25 mM MgCl₂, 0.6 mM NaH₂PO₄, 2.4 mM Na₂HPO₄, 10 mM glucose, 5 mM l-glutamine,
and 10 mM HEPES was used for rinsing, preparation, and transport of the epithelia. All other buffer solutions were based on this basal buffer solution, except glucose, which was reduced to 3 mM for the flux buffer solution or replaced by 3 mM alpha-methyl-glucose (AMG) for the electrophysiological measurements. Mannitol was used to adjust the osmolarity to 280 ± 5 mOsm/L. The pH was adjusted to 7.4 with 1N HCl or NaOH. All buffer solutions were gassed with 100% oxygen. Hypoxia was simulated by changing the gassing from 100% O2 to 99% N2 plus 1% O2 after the equilibration period.

The use of 100% oxygen for gassing the control group might be considered as hyper- rather than normoxic. However, it has to be kept in mind, that oxygen has to be dissolved physically in the buffer solution and cannot be transported as effectively as in vivo. Therefore, it is assumed that the actual amount of oxygen near and inside the tissue is less than 100%. The diffusion distance is further increased by additional layers besides the ‘isolated’ epithelium (basal membrane, mucus, connective tissue) in contrast to cultured cells growing in monolayer. Therefore, only a small part of the 100% oxygen used for gassing will reach the epithelial cells. Moreover, the functional differences observed in our experiments indicate that there is a biologically significant difference in oxygen supply.

4.1.3. Electrical Measurements

Electrical measurements were taken continuously with the aid of a computer-controlled voltage clamp device (Ingenieurbüro für Mess- und Datentechnik, Dipl.-Ing. K. Mußler, Aachen, Germany). All experiments were conducted under short-circuit conditions. The short-circuit current (\(I_{sc}\)) and transepithelial tissue conductance (\(G_t\)) were calculated computationally as described before [5].

In each experiment, the different treatments were assigned to the individual epithelia within one animal according to their \(G_t\) so that at the end of an experimental series, the mean value of \(G_t\) was similar in all treatment groups.

For the measurement of SGLT1 activity, epithelia were preincubated with 2 mM DMOG for 15 min before subjecting part of the epithelia to hypoxia. After 45 min of hypoxia, 0.2 mM phlorizin, an inhibitor of SGLT1 [28], was added to the mucosal buffer solution and the difference in the slope of \(I_{sc}\) before and after this addition (i.e., the loss of net charge transport across the epithelium) was measured.

The slope of \(I_{sc}\), i.e., the decrease in \(I_{sc}\) over time, was calculated using the formula \(m = \frac{I_{sc1} - I_{sc2}}{t1 - t2}\) for one minute before (\(m_b\)) and one minute after (\(m_a\)) the addition of phlorizin [5]. The difference \(\Delta m = m_b - m_a\) (\(\mu\)Eq cm\(^{-2}\) h\(^{-1}\) min\(^{-1}\)) was calculated and used for statistical comparison. By comparing \(\Delta m\), the drop in \(I_{sc}\) could be assessed independently from the individual epithelium’s absolute \(I_{sc}\) value, and thus, the effect of SGLT1 inhibition could be evaluated (see Figure 1a).

After dismounting the epithelia, they were washed in PBS, snap-frozen in liquid nitrogen, and stored at −80 °C for RNA extraction and assessment of the gene expression (see below).

4.1.4. Flux Rate Measurements

The transepithelial transport (‘flux rates’) of radioactively labelled \(^{14}\)C-glucose was measured from the mucosal (‘hot side’, 4 kBq/mL) to the serosal (‘cold side’) side of the epithelium (\(I_{ms}^{glucose}\)).

The buffer solutions for these experiments contained 3 mM glucose on both sides of the epithelium. To trace the transport of the substance across the epithelium, the radioactively labelled substrate was added to the mucosal side, and samples (0.8 mL) were taken from the serosal side every 30 min. The volume removed was replaced with the respective buffer solution and corrected for in flux ratio calculations. The amount of transported substrate could be derived from these measurements. A first flux period was measured without inhibitors to ensure similar flux rates across all epithelia. Then, part of the epithelia was submitted to hypoxia and one of the inhibitors was added to the mucosal side and preincubated for 30 min. In order to identify the transporters involved in the transport of glucose across the epithelium, we applied 0.2 mM phlorizin, 0.5 mM STF-31, and 0.2 mM cytochalasin B as inhibitors for SGLT1, GLUT1, and GLUT2, respectively. The inhibitors were prepared as stock solutions, so that only small volumes were added to the buffer solutions. Phlorizin was dissolved in
ethanol and cytochalasin B and STF-31 in DMSO. The solvents were also added to the control groups, which were pooled to one group because there was no difference in $J_{ms}^{\text{glucose}}$.

In a second experiment, we also tested the effect of preincubating the epithelia with the panhydroxylase inhibitor DMOG (2 mM, dissolved in distilled water) on the STF-31-sensitive $J_{ms}^{\text{glucose}}$. Here, DMOG was added after the initial equilibration period of approximately 30 min, otherwise the same protocol as described above was used.

The activity of radioisotopes was measured as decays per minute (dpm) by photometric measurements (Liquid Scintillation Analyzer Tri-Carb 2810, Perkin Elmer Inc., Waltham, MA, USA). The corresponding amount of substrate was calculated using a simple ratio equation. In each experiment, two samples (0.1 mL) were taken from the 'hot' side, to which the radioactively labelled substrate was added, and their averaged dpm values were used to calculate the specific activity used. Aquasafe® 300 Plus (Fa. Zinsser Analytic, Eschborn, Germany) was used as scintillation fluid. $^{14}$C-glucose was obtained from Hartmann Analytic GmbH (Braunschweig, Germany).

4.2. Cell Culture

CaCo-2 cells were used for cell culture experiments to gain further insights into the mechanisms underlying the functional changes observed in the Ussing chamber experiments. The cells were a generous gift from H.Y. Naim, Institute for Biochemistry, University of Veterinary Medicine, Hannover, Foundation, Germany. They were incubated in a humidified 5% CO$_2$ air atmosphere at 37 °C in Dulbecco’s modified Eagle’s medium (DMEM) with high glucose content supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin/streptomycin and 3 mM L-glutamine. Passages 20–30 were used for the experiments. Cells were seeded either in cell culture flasks of 25 cm$^2$ for protein extraction or on 12-well plates (both greiner bio-one, Frickenhausen, Germany) for RT-qPCR.

All chemicals for cell culture were obtained from Sigma-Aldrich (Darmstadt, Germany).

When the cells were near confluency (>95%), they were washed with PBS once, fresh medium was added, and the respective treatment was applied. DMOG was dissolved in DMEM and added to the fresh medium from a stock solution to an end concentration of 3 mM. The medium for the epithelia to be incubated under 1% O$_2$ was preequilibrated for 20 min in the hypoxic incubator and the cells were put in the incubator without lid in order to support a free exchange with the incubator’s atmosphere.

After the incubation time of 0.5, 1, 3, 6, or 24 h, the cells were washed with ice-cold PBS once and detached mechanically using a cell scraper. All steps were conducted on ice.

For total protein extraction, the cell suspension (in PBS) was centrifuged at 800× g and 4 °C for 5 min and the pellet was resuspended in 500 μL of a lysis buffer consisting of 10 mM EDTA, 4 mM EGTA, 50 mM TRIS buffer, 100 mM β-glycerin-phosphate-disodium pentahydrate, 0.1% Triton X-100, 15 mM sodium orthovanadate, 100 mM sodium pyrophosphate tetrabasic decahydrate, and 2.5 mM NaF (pH 7.4) with a protease and phosphatase inhibitor (100X Halt™ protease and phosphatase inhibitor cocktail, Thermo Fisher Scientific, Dreieich, Germany). The protein concentration was measured with a Tecan Spectra Rainbow Microplate Reader (Tecan Deutschland, Crailsheim, Germany) using the bicinchoninic acid method and bovine serum albumin as standard.

For the evaluation of gene expression, the cells were also spun down at 800× g for 5 min and the pellet was stored at −80 °C until further processing.

4.3. Western Blot Analysis

For Western blot analysis of AMPKα, ACC, and their phosphorylated forms (pAMPKα, pACC), as well as the protein expression of the glucose transporters, the protein samples were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) using 10 μg protein/well. Subsequently, the samples were transferred onto a nitrocellulose membrane (Carl Roth, Karlsruhe, Germany) using the Mini-Protean® system (Bio-rad laboratories, Feldkirchen, Germany). The membrane was preincubated in 5% bovine serum albumin in TRIS-buffered saline containing 0.2% Tween-20 (TBST) at 4 °C over night. On the next day, it was incubated with the primary antibodies
(see Table 1) at room temperature with gentle shaking for two hours. After washing with TBST five times, the membranes were incubated with an HRP-coupled secondary antibody (see Table 1) at room temperature with gentle shaking for one hour. Subsequently, the membranes were rinsed again with TBST five times and once with TBS, then the signal was detected by enhanced chemiluminescence using a G:BOX Chemi XT4 and analyzed with the GeneTools© software (both Syngene, Cambridge, UK). β-Actin or Villin was used as loading control for normalization of each blot.
Table 1. Antibodies used for Western blot.

| Primary Antibody | Manufacturer | Dilution | Secondary Antibody | Manufacturer | Dilution |
|------------------|--------------|----------|--------------------|--------------|----------|
| Acetyl-CoA Carboxylase (C83B10) Rabbit mAb 3676 | Cell Signaling Technology Europe B.V., Frankfurt/Main, Germany | 1:1000 | Anti-rabbit IgG, HRP-linked Antibody 7074 | Cell Signaling Technology Europe B.V., Frankfurt/Main, Germany | 1:5000 |
| Phospho-Acetyl-CoA Carboxylase (Ser79) (D7D11) Rabbit mAb 11818 AMPKα (D5A2) Rabbit mAb 5831 Phospho-AMPKα (Thr172) (40H9) Rabbit mAb 2535 | Antibodies online, Aachen, Germany | 1:1000 | Anti-rabbit IgG, HRP-linked, sc-2077 | Santa Cruz Biotechnology, Heidelberg, Germany | 1:5000 |
| SGLT1, rabbit polyclonal Antibody, ABIN364451 | Abcam, Berlin, Germany | 1:1000 | Anti-rabbit IgG, HRP-linked, preadsorbed, ab195176 | Abcam, Berlin, Germany | 1:10000 |
| GLUT1, sheep polyclonal antibody, ab54263 | Merck Millipore, Darmstadt, Germany | 1:1000 | Anti-rabbit IgG, HRP-linked, sc-2077 | Santa Cruz Biotechnology, Heidelberg, Germany | 1:5000 |
| pGLUT1 (Ser226), rabbit polyclonal antibody, ABN991 | ThermoFisher Scientific, Dreieich, Germany | 1:200 | Anti-rabbit IgG, HRP-linked, sc-2077 | Santa Cruz Biotechnology, Heidelberg, Germany | 1:5000 |
| GLUT2, rabbit polyclonal antibody, PA5-77459 | Santa Cruz Biotechnology, Heidelberg, Germany | 1:1000 | Anti-mouse IgG, HRP-linked, A16072 | Invitrogen, Dreieich, Germany | 1:5000 |
| β-Actin, mouse monoclonal antibody, sc-47778 | ThermoFisher Scientific, Dreieich, Germany | 1:1000 | Anti-rabbit IgG, HRP-linked, sc-2077 | Santa Cruz Biotechnology, Heidelberg, Germany | 1:5000 |
| Villin, rabbit polyclonal antibody, PA5-78222 | | | | | |


4.4. Two-Step Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT-qPCR)

The RNA was extracted from 10 mg of tissue samples and frozen cell pellets, respectively, using the ReliaPrep™ RNA Miniprep System (Promega, Mannheim, Germany) following the manufacturer’s protocol. The RNA concentration and quality were determined with the aid of a spectrophotometer (BioPhotometer, Eppendorf, Wesseling-Berzdorf, Germany). In total, 1 µg of high-quality RNA was used for cDNA synthesis using the GoScript™ Reverse Transcriptase Kit (Promega, Mannheim, Germany) according to the manufacturer’s instructions using a MJ Research PTC-200 Peltier Thermal Cycler (Bio-Rad, Feldkirchen, Germany).

For qPCR, the resulting cDNA was diluted 1:20 and 2 µL were used in a 20 µL reaction volume containing 10 µL of a ready-to-use premix of SYBR Green I dye, dNTPs, stabilizers and enhancers (GoTaq®, Promega, Mannheim, Germany), 112 nM primer mix, and DNase-free water. These mixtures were pipetted in strip tubes (0.1 mL Strips, LTF Labortechnik, Wasserburg, Germany) and processed in a Corbett Rotor-Gene 6000 (Qiagen, Hilden, Germany) at individually optimal protocols (Table 2). A no template control (NTC) with DNase-free water instead of cDNA was applied for each run. qPCR reactions for each sample and gene were run in duplicate to minimize dispensation artefacts. The deviation of $C_T$ of the technical replicates was <0.3. If it was higher, data were discarded, and the run was repeated. The PCR cycles were run using automatic fluorescence emission following each PCR cycle and the amplification specificity was checked after each run by melting curve analysis. The primer sequences and conditions for qPCR are shown in Table 2; the denaturation temperature was always 95 °C and the extension was performed at 60 °C.

The primers were designed with the Primer BLAST tool from the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA) according to known sequences from the basic local alignment search tool (BLAST) in the gene bank database of the NCBI and synthesized by Eurofins MWG (Ebersberg, Germany). The amplicons were sequenced again and the product sequences were verified by BLAST.

The quantification cycle and amplification efficiency of each amplification curve were determined using the Rotor Gene 6000 Series Software 1.7 (Corbett/Qiagen, Hilden, Germany). For analysis of the data, the ‘relative expression software tool’ (REST 2009-RG Mode, Qiagen, Hilden, Germany) established by Pfaffl et al. [42] was used to calculate the relative mRNA expression with reference to the control group incubated at 21% O$_2$ for the CaCo-2 cells and to native tissue that was snap-frozen immediately after the isolation (i.e., not incubated in the Ussing chamber) for the lagomorph jejunum epithelium, respectively, and whose expression was set to 1. The $C_T$ values set by the software were applied after checking them optically.

Normalization of the samples was achieved using the same amounts of RNA for processing and by normalizing the data for the target genes with the aid of the reference genes hypoxanthine guanine phosphoribosyltransferase 1 (HPRT1), peptidylprolyl-isomerase (PPI) A and B and β-actin. The reference genes have been proven to be stable under the experimental conditions applied in our study. Their stability was tested using the programs BestKeeper© (Version 1 by M.W. Pfaffl, Institute of Physiology, Center of Life and Food Sciences, TUM-Weihenstephan, Germany, 2004) and geNorm [43].
Table 2. Primers used for RT-qPCR.

| Gene Name | Gene Bank Accession Number | Primer Sequence (5′–3′) | Annealing Temperature (°C) | Amplicon Length (bp) |
|-----------|----------------------------|--------------------------|-----------------------------|----------------------|
| **CaCo-2** |                            |                          |                             |                      |
| HPRT1     | NM_000194.3                | F: ATGGACAGGACTGAAAGCTCTT R: TGAAATCCAGCGATCTCAACA | 57                          | 118                  |
| PPIA      | NM_021330.5                | F: CGGGAGGAAAACCGTGTACT R: CTGCAAACAGCTAAAGGAGAC  | 59                          | 106                  |
| GLUT1     | NM_005161.3                | F: GAACTCTTCAGCCACTGAGCCG R: ACCACACAGTCTCTCCCAT | 60                          | 114                  |
| GLUT2     | NM_000340.2                | F: CAAATGACCTCAACAGTGAATAA R: AGATGTGGGGCGATCAGTCGT | 57                          | 119                  |
| SGLT1     | NM_000343.3                | F: AGACCCAGCCGGCTCAC R: AACAACATCCCCGCACGCAGGA | 57                          | 120                  |
| **Oryctolagus cuniculus** |                       |                          |                             |                      |
| PPIB      | DQ27941.1                  | F: CCGGTGCTTCTCGTCTCTTT R: TGAGCAAAATCCTCTCTCCCTC | 60                          | 90                   |
| β-actin   | NM_00110683.1              | F: AAACCTGGAACGGTGAAGGTGA R: ACAATCAAAGTCCTCGGCCA | 58                          | 89                   |
| HPRT1     | NM_00105571.1              | F: GTATGCTGAGCAACATGTGCG R: TCCACAGAAATCTGCGCCGTA | 58                          | 106                  |
| GLUT1     | NM_00105897.1              | F: GACAACTGCTCTCCGTATCC R: ATCCACAGAAATCTGCGCCG | 59                          | 104                  |
| GLUT2     | XM_017346915.1             | F: TCACAGCTCCTCCGTATCC R: ATCCACAGAAATCTGCGCCG | 59                          | 118                  |
| SGLT1     | NM_0010692.1               | F: GAGACTGACCGAGCCTGGAG R: CCCGCTTCATAGGCAAACCT | 60                          | 93                   |

F: forward primer; R: reverse primer; bp: base pairs.

4.5. Statistics

The results are described as arithmetic means ± standard deviation (SD) or as box plot representing the median ± 10th, 25th, 75th, and 90th percentile. The significance is expressed as the probability of error (p). Regarding the Ussing chamber experiments, N indicates the number of animals used, and n represents the number of single epithelia for each treatment. For cell culture, each independent experiment with different stocks and passages of the cells is considered as a biological replicate (“N”), while technical replicates are considered as “n”. The data were pooled for each N for statistical analysis. The differences between the mean values of two groups were tested using the repeated-measures one-way analysis of variance (ANOVA) with a subsequent Holm–Sidak or Tukey test as appropriate (Sigma Plot 13.0, Systat Software, Erkrath, Germany). Gene expression levels were compared using a pair wise fixed reallocation randomization test using the REST software [42]. The differences were assumed to be statistically significant if p < 0.05.

Author Contributions: Conceptualization, F.D.; methodology, F.D.; validation, F.D.; formal analysis, F.D.; investigation, F.D.; resources, F.D. and G.G.; data curation, F.D.; writing—original draft preparation, F.D.; writing—review and editing, F.D and G.G.; visualization, F.D.; project administration, F.D.; funding acquisition, F.D.

Funding: This research was funded by the GERMAN RESEARCH FOUNDATION, grant number DE2489/1-1.

Acknowledgments: We thank Anke Schmidt-Mähne, Ines Urbansky, and Petra Klaußner for excellent technical support.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Description                                      |
|--------------|--------------------------------------------------|
| ACC          | Acetyl-CoA-carboxylase                            |
| AMPK         | AMP-activated protein kinase                      |
| ANOVA        | Analysis of variance                             |
| bp           | Base pairs                                       |
| CAMKK        | Calcium/calmodulin-dependent protein kinase kinase|
| DMOG         | Dimethylxalylglycine                             |
| DMSO         | Dimethyl sulfoxide                               |
| dpm          | Decays per minute                                |
| EDTA         | Ethylenediaminetetraacetic acid                  |
| EGTA         | Ethylene glycol-bis(β-aminoethyl ether)-N,N′,N″,N‴-tetraacetic acid |
References

1. Ward, J.B.J.; Keely, S.J. Oxygen in the regulation of intestinal epithelial transport. _J. Physiol._ **2014**, *592*, 2473–2489. [CrossRef] [PubMed]

2. Colgan, S.P.; Taylor, C.T. Hypoxia: An alarm signal during intestinal inflammation. _Nat. Rev. Gastroenterol. Hepatol._ **2010**, *7*, 281–287. [CrossRef] [PubMed]

3. Eltzschig, H.K.; Carmeliet, P. Hypoxia and inflammation. _N. Engl. J. Med._ **2011**, *364*, 656–665. [CrossRef] [PubMed]

4. Semenza, G.L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. _Annu. Rev. Pathol._ **2014**, *9*, 47–71. [CrossRef] [PubMed]

5. Dengler, F.; Rackwitz, R.; Pfannkuche, H.; Gäbel, G. Glucose transport across lagomorph jejunum epithelium is modulated by AMP-activated protein kinase (AMPK) under hypoxia. _J. Appl. Physiol. (1985)_ **2017**, *123*, 1487–1500. [CrossRef] [PubMed]

6. Collins, D.; Kopic, S.; Bachlechner, J.; Ritter, M.; Winter, D.C.; Geibel, J.P. Hypoxia inhibits colonic ion transport via activation of AMP kinase. _Ann. Surg._ **2011**, *254*, 957–963. [CrossRef] [PubMed]

7. Kles, K.A.; Tappenden, K.A. Hypoxia differentially regulates nutrient transport in rat jejunum regardless of luminal nutrient present. _Am. J. Physiol. Gastrointest. Liver Physiol._ **2002**, *283*, 42. [CrossRef]

8. Dengler, F.; Rackwitz, R.; Pfannkuche, H.; Gäbel, G. Coping with Hypoxia: Adaptation of Glucose Transport Mechanisms Across Equine Jejunum Epithelium. _J. Equine Vet. Sci._ **2018**, *69*, 1–10. [CrossRef]

9. Krimi, R.B.; Letteron, P.; Chedid, P.; Nazaret, C.; Ducroc, R.; Marie, J.C. Resistin-like molecule-beta inhibits SGLT-1 activity and enhances GLUT2-dependent jejunal glucose transport. _Diabetes_ **2009**, *58*, 2032–2038. [CrossRef]

10. Kellett, G.L.; Brot-Laroche, E.; Mace, O.J.; Leturque, A. Sugar Absorption in the Intestine: The Role of GLUT2. _Annu. Rev. Nutr._ **2008**, *28*, 35–54. [CrossRef]

11. Gouyon, F.; Cailaud, L.; Carriere, V.; Klein, C.; Dalet, V.; Citadelle, D.; Kellett, G.L.; Thorens, B.; Leturque, A.; Brot-Laroche, E. Simple-sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption: A study in GLUT2-null mice. _J. Physiol._ **2003**, *552*, 823–832. [CrossRef] [PubMed]

12. Lee, M.; Hwang, J.-T.; Lee, H.-J.; Jung, S.-N.; Kang, I.; Chi, S.-G.; Kim, S.-S.; Ha, J. AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells. _J. Biol. Chem._ **2003**, *278*, 39653–39661. [CrossRef] [PubMed]

13. Salle-Lefort, S.; Miard, S.; Nolin, M.-A.; Boivin, L.; Fare, S.-E.; Debigare, R.; Picard, F. Hypoxia upregulates Malat1 expression through a CaMKK/AMPK/HIF-1alpha axis. _Int. J. Oncol._ **2016**, *49*, 1731–1736. [CrossRef] [PubMed]

14. Tan, C.D.; Smolenski, R.T.; Harhun, M.I.; Patel, H.K.; Ahmed, S.G.; Wanisch, K.; Yáñez-Muñoz, R.J.; Baines, D.L. AMP-activated protein kinase (AMPK)-dependent and -independent pathways regulate hypoxic inhibition of transepithelial Na+ transport across human airway epithelial cells. _Br. J. Pharmacol._ **2012**, *167*, 368–382. [CrossRef] [PubMed]
15. Faubert, B.; Vincent, E.E.; Poffenberger, M.C.; Jones, R.G. The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator. Cancer Lett. 2015, 356, 165–170. [CrossRef]
16. Hardie, D.G.; Carling, D. The AMP-activated protein kinase–fuel gauge of the mammalian cell? Eur. J. Biochem. 1997, 246, 259–273. [CrossRef] [PubMed]
17. Hardie, D.G.; Ashford, M.L.J. AMPK: Regulating Energy Balance at the Cellular and Whole Body Levels. Physiology 2014, 29, 99–107. [CrossRef]
18. Woods, A.; Dickerson, K.; Heath, R.; Hong, S.-P.; Momcilovic, M.; Johnstone, S.R.; Carlson, M.; Carling, D. Ca\(^{2+}\)/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2005, 2, 21–33. [CrossRef]
19. Hardie, D.G.; Schaffer, B.E.; Brunet, A. AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs. Trends Cell Biol. 2016, 26, 190–201. [CrossRef]
20. Lang, F.; Föller, M. Regulation of ion channels and transporters by AMP-activated kinase (AMPK). Channels 2014, 8, 20–28. [CrossRef]
21. Schoots, I.G.; Bijlsma, P.B.; Koivunen, P. Hypoxia-inducible factor prolyl 4-hydroxylases: Common and specific roles. Curr. Opin. Genet. Dev. 1998, 8, 588–594. [CrossRef]
22. Pugh, C.W.; Ratcliffe, P.J. New horizons in hypoxia signaling pathways. Exp. Cell Res. 2017, 356, 116–121. [CrossRef] [PubMed]
23. Schofield, C.J.; Ratcliffe, P.J. Signalling hypoxia by HIF hydroxylases. Biochem. Biophys. Res. Commun. 2005, 338, 617–626. [CrossRef] [PubMed]
24. Scholz, C.C.; Rodriguez, J.; Pickel, C.; Burr, S.; Fabrizio, J.-A.; Nolan, K.A.; Spielmann, P.; Cavadas, M.A.S.; Crifo, B.; Halligan, D.N.; et al. FIH Regulates Cellular Metabolism through Hydroxylation of the Deubiquitinase OTUB1. PLoS Biol. 2016, 14, e1002347. [CrossRef] [PubMed]
25. Meunier, V.; Bourrié, M.; Berger, Y.; Fabre, G. The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol. Toxicol. 1995, 11, 187–194. [CrossRef] [PubMed]
26. Santos, A.; Goncalves, P.; Araujo, J.R.; Martel, F. Intestinal permeability to glucose after experimental traumatic brain injury: Effect of gadopentetate dimeglumine administration. Basic Clin. Pharmacol. Toxicol. 2008, 103, 247–254. [CrossRef]
27. Zheng, Y.; Scow, J.S.; Duenes, J.A.; Sarr, M.G. Mechanisms of glucose uptake in intestinal cell lines: Role of GLUT2. Surgery 2012, 151, 13–25. [CrossRef] [PubMed]
28. Estensen, R.D.; Plagemann, P.G.W. Cytochalasin B: Inhibition of Glucose and Glucosamine Transport*. Proc. Natl. Acad. Sci. USA 1972, 69, 1430–1434. [CrossRef] [PubMed]
29. Chan, D.A.; Sutphin, P.D.; Nguyen, P.; Turcotte, S.; Lai, E.W.; Bank, A.; Reynolds, G.E.; Chi, J.-T.; Wu, J.; Solow-Cordero, D.E.; et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med. 2011, 3, 94ra70. [CrossRef]
30. Kraus, D.; Reckenbeil, J.; Veit, N.; Kuerpig, S.; Meisenheimer, M.; Beier, I.; Stark, H.; Winter, J.; Probstmeier, R. Targeting glucose transport and the NAD pathway in tumor cells with STF-31: A re-evaluation. Cell Oncol. (Dordr) 2012, 35, 1–7. [CrossRef] [PubMed]
37. Lee, E.E.; Ma, J.; Sacharidou, A.; Mi, W.; Salato, V.K.; Nguyen, N.; Jiang, Y.; Pascual, J.M.; North, P.E.; Shaul, P.W.; et al. A Protein Kinase C Phosphorylation Motif in GLUT1 Affects Glucose Transport and is Mutated in GLUT1 Deficiency Syndrome. *Mol. Cell* 2015, 58, 845–853. [CrossRef]

38. Yan, H.; Zhang, D.-X.; Shi, X.; Zhang, Q.; Huang, Y.-S. Activation of the prolyl-hydroxylase oxygen-sensing signal cascade leads to AMPK activation in cardiomyocytes. *J. Cell. Mol. Med.* 2012, 16, 2049–2059. [CrossRef]

39. Gusarova, G.A.; Dada, L.A.; Kelly, A.M.; Brodie, C.; Witters, L.A.; Chandel, N.S.; Sznajder, J.I. Alpha1-AMP-activated protein kinase regulates hypoxia-induced Na,K-ATPase endocytosis via direct phosphorylation of protein kinase C zeta. *Mol. Cell. Biol.* 2009, 29, 3455–3464. [CrossRef]

40. Seo, K.; Seo, S.; Ki, S.H.; Shin, S.M. Sestrin2 inhibits hypoxia-inducible factor-1alpha accumulation via AMPK-mediated prolyl hydroxylase regulation. *Free Radic. Biol. Med.* 2016, 101, 511–523. [CrossRef]

41. Mungai, P.T.; Waypa, G.B.; Jairaman, A.; Prakriya, M.; Dokic, D.; Ball, M.K.; Schumacker, P.T. Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. *Mol. Cell. Biol.* 2011, 31, 3531–3545. [CrossRef] [PubMed]

42. Pfaffl, M.W.; Horgan, G.W.; Dempfle, L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. *Nucleic Acids Res.* 2002, 30, e36. [CrossRef] [PubMed]

43. Vandesompele, J.; de Preter, K.; Pattyn, F.; Poppe, B.; van Roy, N.; de Paepe, A.; Speleman, F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.* 2002, 3, RESEARCH0034. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).